Optimizerx CORP Schedule 13G passive stakes

Kennedy Capital Management LLC has reported a beneficial ownership of 1,248,899 shares, representing 6.7% of OptimizeRx Corp's common stock.

Royce & Associates LP has disclosed beneficial ownership of 1,089,398 shares, representing 5.81% of the outstanding common stock of OptimizeRx Corp.

The Vanguard Group has reported a 0% beneficial ownership in OptimizeRx Corp common stock following an internal realignment.

The Vanguard Group has reported a 5.7% beneficial ownership stake in OptimizeRx Corp, holding over 1 million shares as of September 30, 2025.

Royce & Associates LP, an investment adviser, has filed an amended Schedule 13G disclosing a 4.27% beneficial ownership stake in OptimizeRx Corp.

The Vanguard Group has filed an Amendment No. 3 to its Schedule 13G, disclosing a 4.98% passive beneficial ownership in OptimizeRx Corp's Common Stock as of March 31, 2025.

An amended Schedule 13G filing reveals that Samjo Management, LLC and Andrew N. Wiener beneficially own a combined 50 shares, representing 0.0% of OptimizeRx Corporation's common stock, indicating a passive and non-influential holding.

Investment adviser Royce & Associates LP has reported a 5.81% passive beneficial ownership stake in OptimizeRx Corp, holding 1,069,560 shares of common stock as of December 31, 2024.

First Light Asset Management, LLC and Mathew P. Arens have filed an amended Schedule 13G, reporting 0% beneficial ownership of OptimizeRx Corporation's common stock as of December 31, 2024.